The subscription period in NeoDynamics’ issue of units prior to planned listing on Spotlight Stock Market begins today

The company’s principal shareholder is also the largest investor in the issue of units though both subscription commitments and a gratuitous guarantee subscription. Among other things, the proceeds from the issue of units are planned to finance the final development of the commercial version of the company’s product, NeoNavia, clinical studies to validate NeoNavia as well as marketing and launch costs for NeoNavia. Prospectus, teaser and subscription form are available via the websites of the company (www.neodynamics.se) and Sedermera Fondkommission (www.sedermera.se). The investment documents are also available via the website of Spotlight Stock Market (www.spotlightstockmarket.com). Nordnet Bank AB is acting as Selling Agent in the issue of units, which will also be marketed in Denmark, Norway and Finland.

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, NeoDynamics have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing the development of the commercial version of NeoNavia. Together with several design and usability features it integrates micropulse technology with multiple needle options to provide maximum flexibility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is also considered suitable for cancer diagnostics in other organs such as prostate, lung, kidney and liver.

Anna Eriksrud, CEO at NeoDynamics, comments

“I would like to welcome you as an investor to be a part of our journey towards provide better care of breast cancer patients. At NeoDynamics, we have developed a new patented technology based on micro-pulses, which solves several key problems with breast cancer patients' biopsies, which can also replace the obsolete technologies used today. By doing this we can also create great added value, both for patients and for healthcare and, in the long run, for society as a whole. The most important reason to invest in NeoDynamics, besides the market potential, is that we are now part of the battle against breast cancer and in that battle, I’m convinced that we can make a huge difference. We would like to contribute to better diagnostics methods for the millions of women across the world that are affected by breast cancer every year and thereby providing increased chances of survival.”

The issue in summary

Subscription period: October 31 – November 14, 2018.

Issue price: SEK 16.40 per unit. One unit consists of two (2) shares and one (1) associated free warrant of series TO 1. The price per share is thus SEK 8.20.

Subscription post: The minimum subscription post is 375 units, corresponding to SEK 6,150.

Extent of issue: The issue encompasses up to 6,160,000 shares and 3,080,000 series TO 1 warrants, amounting to SEK 50,512,000 and SEK 25,256,000, respectively. The established minimum level for carrying out the issue is 3,080,000 units, amounting to SEK 50,512,000.

Number of shares prior to issue: 9,143,520 shares.

Valuation (pre-money): Approximately SEK 75 million.

Subscription commitments and free guarantee subscription: The company has received subscription commitments totalling approximately SEK 31 million and a free guarantee subscription (top-down) totalling SEK 6 million, equating to approximately 73 percent of the total issue volume.

Listing on Spotlight Stock Market: NeoDynamics’ shares and the associated series TO 1 warrants are planned to be listed on Spotlight Stock Market. The planned first day of trading is the 7th of December 2018. The share’s ticker is NEOD.

ISIN code: SE0011563410 for the shares and SE0011725605 for the series TO 1 warrants.

Investor meetings

In connection with the IPO, NeoDynamics will present the business and future plans at a number of investment events. See schedule below for details.

Financial advisor

Sedermera Fondkommission is the financial advisor to NeoDynamics in connection with the issue of units and the planned listing on Spotlight Stock Market. Nordnet Bank AB is acting as Selling Agent in the issue of units.

For further information about the IPO and the planned listing, please contact:

Sedermera Fondkommission

Telephone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For further information about NeoDynamics, please contact:                            

Anna Eriksrud, CEO NeoDynamics AB (publ)

Telephone: +46 8 522 79 667

E-mail: anna.eriksrud@neodynamics.se

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, NeoDynamics have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.